Share Price and Basic Stock Data
Last Updated: January 16, 2026, 11:11 pm
| PEG Ratio | -1.70 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Evoq Remedies Ltd operates within the pharmaceuticals sector, focusing on developing and marketing various medicinal products. The company reported a price of ₹2.77 and a market capitalization of ₹6.90 Cr. Over the past few years, Evoq has witnessed significant fluctuations in revenue. Sales stood at ₹20.39 Cr for the fiscal year ending March 2023, a notable increase from ₹16.78 Cr in March 2022. However, a sharp decline was observed in FY 2024, where sales dropped to ₹4.05 Cr. The trailing twelve months (TTM) revenue, as of the latest reporting, was ₹37.27 Cr, reflecting an increase in sales momentum, particularly in the latter half of FY 2025, with quarter-on-quarter sales rising to ₹25.51 Cr by September 2025. This indicates a recovery trajectory after a period of downturn, although the substantial drop in the previous fiscal year raises concerns regarding revenue sustainability.
Profitability and Efficiency Metrics
Profitability at Evoq Remedies has been inconsistent, as evidenced by the operating profit margins (OPM) which stood at -3.72% for the most recent period. The company recorded a net profit of ₹1.76 Cr in the TTM, but a closer look reveals that net profits were significantly affected by fluctuating sales and operational inefficiencies. For instance, net profit for March 2023 was ₹1.31 Cr, decreasing to ₹0.05 Cr by September 2023. Evoq’s return on equity (ROE) stood at 0.26%, indicating limited returns relative to shareholder equity. The cash conversion cycle (CCC), at 231.85 days, suggests inefficiencies in managing working capital, particularly with inventory and receivables management. In contrast, the company has shown resilience in generating other income, particularly ₹6.02 Cr in FY 2023, which contributed positively to its overall profitability.
Balance Sheet Strength and Financial Ratios
Evoq Remedies exhibits a relatively strong balance sheet, characterized by zero borrowings, which provides a solid foundation for financial stability. The company’s reserves have increased to ₹19.69 Cr, reflecting an improvement in retained earnings over time. However, the price-to-book value (P/BV) ratio is notably low at 0.14x, indicating that the stock may be undervalued relative to the company’s net worth. The company’s current ratio of 9.10x suggests excellent short-term liquidity, far above the typical sector benchmark, which implies a strong capability to meet short-term obligations. Nevertheless, the interest coverage ratio (ICR) at 0.00x signals that Evoq does not have any interest-bearing debt, which, while reducing financial risk, may also indicate underutilization of leverage for growth. The return on capital employed (ROCE) at 0.35% is significantly lower than desirable, indicating inefficiencies in capital utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Evoq Remedies has undergone significant changes, particularly in the promoter stake, which has decreased from 73.53% in March 2022 to 11.21% by September 2025. This substantial drop in promoter holding raises concerns about insider confidence in the company’s future prospects. Conversely, public ownership has surged to 88.79%, reflecting growing interest from retail investors. With a total of 1,679 shareholders as of September 2025, the increased public stake could signal a potential shift in ownership dynamics. However, the lack of institutional interest, with foreign institutional investors (FIIs) and domestic institutional investors (DIIs) reported as N/A, suggests that institutional confidence in Evoq remains low. This absence of institutional backing may hinder the company’s ability to raise capital for future expansion.
Outlook, Risks, and Final Insight
The outlook for Evoq Remedies is mixed, characterized by both opportunities and significant risks. On one hand, the recent recovery in revenue and a strong balance sheet position offer potential for growth. The ability to stabilize and enhance profitability will be critical, especially given the high cash conversion cycle and low ROCE. Risks include reliance on fluctuating sales trends and a diminishing promoter stake, which may signal a lack of strategic direction. Furthermore, the absence of institutional investors may limit access to capital, impacting future expansion plans. Evoq must navigate these challenges effectively while leveraging its financial strengths to restore investor confidence and enhance operational efficiency. A successful turnaround could position the company favorably within the competitive pharmaceuticals landscape, but failure to address these risks may lead to continued volatility in performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.97 Cr | 1,115.98 | 52.27 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 4.93 | 11.85 | 15.79 | 4.60 | 3.90 | 0.15 | 0.00 | 11.76 | 25.51 |
| Expenses | 1.71 | 4.20 | 11.12 | 15.48 | 8.64 | 3.83 | 1.87 | 1.63 | 12.36 | 26.46 |
| Operating Profit | 1.05 | 0.73 | 0.73 | 0.31 | -4.04 | 0.07 | -1.72 | -1.63 | -0.60 | -0.95 |
| OPM % | 38.04% | 14.81% | 6.16% | 1.96% | -87.83% | 1.79% | -1,146.67% | -5.10% | -3.72% | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 0.00 | 2.26 | 0.01 | 2.40 | 1.06 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Profit before tax | 1.05 | 0.73 | 0.73 | 0.31 | 1.98 | 0.07 | 0.54 | -1.62 | 1.76 | 0.08 |
| Tax % | 22.86% | 0.00% | 50.68% | 0.00% | 33.84% | 28.57% | 29.63% | 0.00% | 2.27% | 25.00% |
| Net Profit | 0.81 | 0.73 | 0.36 | 0.31 | 1.31 | 0.05 | 0.38 | -1.62 | 1.71 | 0.05 |
| EPS in Rs | 810.00 | 730.00 | 0.26 | 0.23 | 0.96 | 0.04 | 0.28 | -0.65 | 0.69 | 0.02 |
Last Updated: December 27, 2025, 1:04 am
Below is a detailed analysis of the quarterly data for Evoq Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 25.51 Cr.. The value appears strong and on an upward trend. It has increased from 11.76 Cr. (Mar 2025) to 25.51 Cr., marking an increase of 13.75 Cr..
- For Expenses, as of Sep 2025, the value is 26.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.36 Cr. (Mar 2025) to 26.46 Cr., marking an increase of 14.10 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.95 Cr.. The value appears to be declining and may need further review. It has decreased from -0.60 Cr. (Mar 2025) to -0.95 Cr., marking a decrease of 0.35 Cr..
- For OPM %, as of Sep 2025, the value is -3.72%. The value appears strong and on an upward trend. It has increased from -5.10% (Mar 2025) to -3.72%, marking an increase of 1.38%.
- For Other Income, as of Sep 2025, the value is 1.06 Cr.. The value appears to be declining and may need further review. It has decreased from 2.40 Cr. (Mar 2025) to 1.06 Cr., marking a decrease of 1.34 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.04 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 1.76 Cr. (Mar 2025) to 0.08 Cr., marking a decrease of 1.68 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 2.27% (Mar 2025) to 25.00%, marking an increase of 22.73%.
- For Net Profit, as of Sep 2025, the value is 0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 1.71 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 1.66 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.69 (Mar 2025) to 0.02, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:23 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | 37.27 |
| Expenses | 3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 | 38.82 |
| Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 | -1.55 |
| OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% | -4.16% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | 2.41 | 3.46 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.07 |
| Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 | 1.84 |
| Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | ||
| Net Profit | 0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | 1.76 |
| EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 | 0.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | 51.39% | 48.62% | -72.22% | -80.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 151.39% | -2.77% | -120.85% | -7.78% |
Evoq Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -11% |
| TTM: | 190% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -56% |
| TTM: | -80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -43% |
| 1 Year: | -60% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:51 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 | 24.90 |
| Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 | 19.69 |
| Borrowings | 0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 | 0.00 |
| Other Liabilities | 2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 | 7.63 |
| Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 52.22 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 | 0.20 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | 52.02 |
| Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 52.22 |
Below is a detailed analysis of the balance sheet data for Evoq Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.90 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.90 Cr..
- For Reserves, as of Sep 2025, the value is 19.69 Cr.. The value appears strong and on an upward trend. It has increased from 19.64 Cr. (Mar 2025) to 19.69 Cr., marking an increase of 0.05 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.63 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.47 Cr. (Mar 2025) to 7.63 Cr., marking an increase of 2.16 Cr..
- For Total Liabilities, as of Sep 2025, the value is 52.22 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 50.01 Cr. (Mar 2025) to 52.22 Cr., marking an increase of 2.21 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.22 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.02 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 52.02 Cr.. The value appears strong and on an upward trend. It has increased from 49.79 Cr. (Mar 2025) to 52.02 Cr., marking an increase of 2.23 Cr..
- For Total Assets, as of Sep 2025, the value is 52.22 Cr.. The value appears strong and on an upward trend. It has increased from 50.01 Cr. (Mar 2025) to 52.22 Cr., marking an increase of 2.21 Cr..
Notably, the Reserves (19.69 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.02 | -0.01 | 0.95 | -6.70 | -13.31 | -5.88 | -2.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 | 267.54 |
| Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 | 61.90 |
| Days Payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 | 97.59 |
| Cash Conversion Cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 | 231.85 |
| Working Capital Days | 1.12 | 1.21 | 26.23 | 436.56 | 440.90 | 2,263.00 | 1,369.06 |
| ROCE % | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
| Diluted EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
| Cash EPS (Rs.) | 0.05 | 0.33 | 1.19 | 0.80 | 713.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
| Revenue From Operations / Share (Rs.) | 4.72 | 2.98 | 14.99 | 12.34 | 10024.80 |
| PBDIT / Share (Rs.) | 0.07 | 0.45 | 1.68 | 1.08 | 953.90 |
| PBIT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.08 | 953.90 |
| PBT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.07 | 953.90 |
| Net Profit / Share (Rs.) | 0.03 | 0.33 | 1.19 | 0.80 | 713.80 |
| PBDIT Margin (%) | 1.50 | 15.26 | 11.22 | 8.71 | 9.51 |
| PBIT Margin (%) | 1.09 | 15.08 | 11.21 | 8.71 | 9.51 |
| PBT Margin (%) | 1.09 | 15.08 | 11.20 | 8.68 | 9.51 |
| Net Profit Margin (%) | 0.75 | 11.16 | 7.94 | 6.50 | 7.12 |
| Return on Networth / Equity (%) | 0.19 | 1.79 | 6.53 | 4.71 | 96.93 |
| Return on Capital Employeed (%) | 0.28 | 2.42 | 9.22 | 6.31 | 128.45 |
| Return On Assets (%) | 0.17 | 1.22 | 4.64 | 3.27 | 8.87 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.16 | 0.38 | 0.35 | 0.01 |
| Asset Turnover Ratio (%) | 0.27 | 0.11 | 0.59 | 0.81 | 1.46 |
| Current Ratio (X) | 9.10 | 3.17 | 3.45 | 3.28 | 1.10 |
| Quick Ratio (X) | 8.69 | 2.90 | 3.25 | 3.20 | 1.08 |
| Inventory Turnover Ratio (X) | 4.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 1761.31 | 316.78 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 1246.62 | 237.30 | 0.00 |
| Enterprise Value (Cr.) | 6.16 | 15.91 | 27.09 | 35.80 | 0.00 |
| EV / Net Operating Revenue (X) | 0.52 | 3.92 | 1.33 | 2.13 | 0.00 |
| EV / EBITDA (X) | 34.78 | 25.71 | 11.83 | 24.47 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
| Price / BV (X) | 0.14 | 0.46 | 0.71 | 1.33 | 0.00 |
| Price / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
| EarningsYield | 0.01 | 0.03 | 0.09 | 0.03 | 0.00 |
After reviewing the key financial ratios for Evoq Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has decreased from 0.33 (Mar 24) to 0.05, marking a decrease of 0.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.72. It has increased from 2.98 (Mar 24) to 4.72, marking an increase of 1.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.07, marking a decrease of 0.38.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.33 (Mar 24) to 0.03, marking a decrease of 0.30.
- For PBDIT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has decreased from 15.26 (Mar 24) to 1.50, marking a decrease of 13.76.
- For PBIT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For PBT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For Net Profit Margin (%), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 5. It has decreased from 11.16 (Mar 24) to 0.75, marking a decrease of 10.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 15. It has decreased from 1.79 (Mar 24) to 0.19, marking a decrease of 1.60.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 10. It has decreased from 2.42 (Mar 24) to 0.28, marking a decrease of 2.14.
- For Return On Assets (%), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 5. It has decreased from 1.22 (Mar 24) to 0.17, marking a decrease of 1.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. It has increased from 0.11 (Mar 24) to 0.27, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 9.10. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 9.10, marking an increase of 5.93.
- For Quick Ratio (X), as of Mar 25, the value is 8.69. This value exceeds the healthy maximum of 2. It has increased from 2.90 (Mar 24) to 8.69, marking an increase of 5.79.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 4.40, marking an increase of 4.40.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.16. It has decreased from 15.91 (Mar 24) to 6.16, marking a decrease of 9.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 3.92 (Mar 24) to 0.52, marking a decrease of 3.40.
- For EV / EBITDA (X), as of Mar 25, the value is 34.78. This value exceeds the healthy maximum of 15. It has increased from 25.71 (Mar 24) to 34.78, marking an increase of 9.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For Price / BV (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 1. It has decreased from 0.46 (Mar 24) to 0.14, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Evoq Remedies Ltd:
- Net Profit Margin: 0.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.28% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 8.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 4.02 (Industry average Stock P/E: 52.27)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1106, Empire Business Hub, Ahmedabad Gujarat 380060 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhumishth Patel | Managing Director |
| Mr. Narendrakumar Patel | Non Executive Director |
| Mr. Harsh Kothari | Independent Director |
| Ms. Pushpa Joshi | Independent Director |
FAQ
What is the intrinsic value of Evoq Remedies Ltd?
Evoq Remedies Ltd's intrinsic value (as of 17 January 2026) is ₹0.15 which is 94.72% lower the current market price of ₹2.84, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹7.07 Cr. market cap, FY2025-2026 high/low of ₹8.28/2.11, reserves of ₹19.69 Cr, and liabilities of ₹52.22 Cr.
What is the Market Cap of Evoq Remedies Ltd?
The Market Cap of Evoq Remedies Ltd is 7.07 Cr..
What is the current Stock Price of Evoq Remedies Ltd as on 17 January 2026?
The current stock price of Evoq Remedies Ltd as on 17 January 2026 is ₹2.84.
What is the High / Low of Evoq Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Evoq Remedies Ltd stocks is ₹8.28/2.11.
What is the Stock P/E of Evoq Remedies Ltd?
The Stock P/E of Evoq Remedies Ltd is 4.02.
What is the Book Value of Evoq Remedies Ltd?
The Book Value of Evoq Remedies Ltd is 17.9.
What is the Dividend Yield of Evoq Remedies Ltd?
The Dividend Yield of Evoq Remedies Ltd is 0.00 %.
What is the ROCE of Evoq Remedies Ltd?
The ROCE of Evoq Remedies Ltd is 0.35 %.
What is the ROE of Evoq Remedies Ltd?
The ROE of Evoq Remedies Ltd is 0.26 %.
What is the Face Value of Evoq Remedies Ltd?
The Face Value of Evoq Remedies Ltd is 10.0.